NDAVAGINALINSERT, EXTENDED RELEASE
Approved
Mar 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
FEMRING (estradiol acetate) by Millicent Pharma is characteristics. Approved for moderate to severe vasomotor symptoms due to menopause (), moderate to severe vulvar, vaginal atrophy due to menopause () 1. First approved in 2003.
Drug data last refreshed 4h ago · AI intelligence enriched 7h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FEMRING is a vaginal insert delivering estradiol acetate in an extended-release formulation approved for moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause. It works by binding to estrogen receptors in target tissues to restore circulating estrogen levels and modulate pituitary gonadotropin secretion. The estradiol acetate is metabolized to estradiol, the principal intracellular human estrogen.
$7MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D spending ($7M) signals a contracting team focused on lifecycle extension and generic transition planning.
Mechanism of Action
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indications (3)
Worked on FEMRING at Millicent Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.